Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies.
S. A. Wild, I. G. Cannell, K. Kania, A. Nicholls, D. Bressan, CRUK IMAXT Grand Challenge Team, G. J. Hannon, K. Sawicka
The paper uses clonal transcriptomics to identify mechanisms of chemoresistance in TNBC and suggests asparagine deprivation as a potential combination therapy.
bioRxiv · Dec 9, 2021Cancer Biology